|13 December, 2019

Saudi Arabia to set up region's first cancer database

The Saudi Society of Clinical Pharmacy (SSCP) and AstraZeneca Saudi Arabia have signed a MoU which will oversee the introduction of the new group.

Image used for illustrative purpose. Male doctor standing looking out hospital window.

Image used for illustrative purpose. Male doctor standing looking out hospital window.

Gettyimages
Saudi Arabia has become the first Middle East country to launch a new initiative in the effective management of cancer treatment with the establishment of a ‘Saudi Oncology Health Economics Expert Group’ (Sharp).
 
The Saudi Society of Clinical Pharmacy (SSCP) and AstraZeneca Saudi Arabia have signed a MoU which will oversee the introduction of the new group.
 
As per the deal, Sharp will create a database to evaluate cancer treatments, which in turn will inform clinical decisions to provide targeted expenditure on the most effective treatments for the disease.
 
It will also provide a platform for cancer patients to share their thoughts and experiences of different treatments.
 
The Sharp initiative has been launched in line with the National Transformation Program which aims to improve health service quality and clinical efficiency. The agreement also embodies the partnership concept between the public and private sectors in the oncology field.
 
The introduction of Sharp by SSCP and AstraZeneca will see the establishment of a consultancy council with members composed of Saudi experts and decision makers from the public oncology sector, said the statement from SSCP.
 
Cancer patients and survivors will also attend to share their treatment experiences, it stated.
 
The outcome will be the introduction of a permanent set of recommendations around the process of cancer treatment decision-making in order to ensure expenditure is targeted to the most effective treatments, it added.
 
The establishment of Sharp as an important step in the availability of effective platforms to manage cancer treatments, remarked SSCP President Dr Ahmed Al Jedai after signing the agreement with AstraZeneca’s GCC Regional President Dr Ismael Shahadah.
 
“Cancer is one of the main causes of death in Saudi Arabia. The Saudi Health Council recorded 16,000 cases in 2018 and the Saudi Oncology Society estimated the average cost of treating a cancer patient was SR1 million ($266,520) per year. Sharp will help reduce these costs,” said Dr Al Jedai.
 
Dr Shahadah, lauding the partnership with SSCP, said: "As well as creating a database to assess the most effective treatments it will also provide support for people working in the clinical pharmacy sector and raise pharmacological education."
 
A Riyadh-based organisation, SSCP, is unique in the Arab region. It was established under the umbrella of the Saudi Commission for Health Specialties by a group of Saudi pharmacists.
 
It aims to enhance the clinical pharmacy role and develop the profession by providing scientific support and evidence-based scientific resources to ensure safe treatment use. It also aims to raise awareness of the role of clinical pharmacists in the wider society.-TradeArabia News Service

Copyright 2019 Al Hilal Publishing and Marketing Group Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.

More From Business